Out of consecutive 408 patients who had positive RT-PCR tests, a total of 27 patients who met the inclusion criteria were identified. The flowchart of the study is shown in Fig. 2. There were 7 patients [4 men, 3 women; median age: 41 years (29–65 years)] in the non-progressive group and 20 patients [8 men, 12 women; median age: 57 years (23–81) years] in the progressive group. Table 1 demonstrates the clinical characteristics of the two groups of patients.
Fig. 2 The flowchart of the study
Table 1 Patient demographics and clinical characteristics of the two groups of COVID-19 patients
Parameter Non-progressive group (n = 7) Progressive group (n = 20) p
Age 41 (29–65) 57 (23–81) 0.653
Sex 0.662
 Male 4 (57.1%) 8 (40%)
 Female 3 (42.8%) 12 (60%)
Comorbidities 3 (42.8%) 11(55%)
 Hypertension 1 (14.3%) 9 (45%) 0.204
 Diabetes mellitus 3 (42.9%) 2 (10%) 0.091
 Chronic renal failure 0 (0) 1 (5%) 1.000
 Malignancy 1 (14.3%) 1 (5%) 0.459
Treatment
 Hydorxychloroquine 6 (85.7%) 18 (90%) 1.000
 Azithromycin ± or other antibiotics 4 (57.1%) 11 (55%) 1.000
 Oseltamivir 3 (42.9%) 7 (35%) 1.000
 Favipiravir 1 (14.3%) 9 (45%) 0.204
 LMWH 0 (0) 6 (30%) 0.155
Length of hospital stay (day) 5 (0–17) 12.5 (0–29) 0.035
ICU admission 0 (0) 6 (30%) 0.155
Survival 1.000
 Dead 0 (0) 1 (5%)
 Alive 7 (100%) 19 (95%)
Data are n (%) or median (minimum–maximum)
ICU intensive care unit, LMWH low-molecular-weight heparin